by David N. Franz, MD; Gary W. Mathern, MD; and Elizabeth A. Thiele, MD, PhD
Our featured experts provide an overview of the role of mammalian target of rapamycin (mTOR) inhibitor therapy in targeting the underlying pathophy......READ MORE
by David N. Franz, MD; Gary W. Mathern, MD; and Elizabeth A. Thiele, MD, PhD
Our knowledge of tuberous sclerosis complex (TSC) has expanded greatly with the discovery of the critical role of dysregulated mammalian target of ......READ MORE
Although tuberous sclerosis complex (TSC) can affect virtually any organ in the body, a great deal of the morbidity in patients with the genetic di......READ MORE
Tuberous sclerosis complex (TSC) is a rare, multisystem, genetic disorder resulting from mutations in TSC1 and TSC2. Genetic testing may be helpful......READ MORE
The early identification of tuberous sclerosis complex (TSC) allows for the early implementation of interventions and careful monitoring that may h......READ MORE
Tuberous sclerosis complex (TSC) is a rare, multisystem, genetic disease with variable disease features that may include benign brain tumors, seizu......READ MORE
